Episodebeskrivelse
FLGR-242 is being called a smarter, longer-acting follistatin. John examines the advertised construct, the activin-sparing and 19-day half-life claims, the difference between pathway evidence and product evidence, and why transformation photos cannot establish pharmacology or safety.
Nettsted: c8cc7b72-7bf7-4a91-b244-e1418d70a491.libsyn.com

